← Eichor
Study identifier: NCT07587268 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Molecular Profiling for Risk Stratification in Appendiceal Cancer

Condition: Appendiceal Cancer · Appendiceal Adenocarcinoma  ·  Sponsor: City of Hope Medical Center

PhaseN/A
Planned participants400
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort. The study includes DNA methylation profiling and m6A epitranscriptomic profiling to define molecular subtypes, evaluate associations with clinicopathologic features, and develop molecular risk scores for prognostic stratification. The primary goal is to determine whether DNA methylation- and m6A-based molecular features can complement conventional histopathologic grading and improve risk stratification.

This description comes directly from the study's public registry record.

Talk to the study team

Ajay Goel  ·  6262184673  ·  ajgoel@coh.org

Always discuss trial participation with your own doctor first.

Locations (1)

City of Hope Medical CenterDurate, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07587268